B cells play a finely balanced game as they mutate their antibody genes to generate antibody diversity. In this issue of Oncogene, Nilsen et al. show that if this process is upset by removing Ung uracil-DNA glycosylase, spontaneous B-cell lymphomas arise.
Antibodies are inarguably the most versatile proteins we produce. Humans possess a vast number of unique antibodies with different amino-acid sequences in the variable half of the protein molecule which binds to foreign pathogens. All of these variable regions are attached to several constant portions which deliver the knockout punch by neutralizing the invaders. This diversity is accomplished by relatively few inherited genes that encode the variable and constant regions, which are then modified through a process of somatic hypermutation and heavy chain class recombination. This makes B lymphocytes, where antibodies are produced, the master cells of variation.
It turns out that B cells pay a price for their ability to generate diverse antibody molecules. In this issue of Oncogene, Lindahl, Barnes and colleagues (Nilsen et al., 2003) report that mice deficient of Ung uracil-DNA glycosylase develop B-cell tumors. Ung was shown to be a key player in antibody diversity in a stunning series of experiments by Neuberger and colleagues last year (Di Noia and Neuberger, 2002; Petersen-Mahrt et al., 2002) . Uracils are generated in DNA through deamination of cytosines by the activation-induced cytosine deaminase (AID) protein. Mice and humans deficient in AID have no hypermutation in their variable genes and no recombination of their constant genes Revy et al., 2000) . Since AID is only expressed in B cells, uracils likely accumulate in variable genes and in the switch regions where constant gene recombination occurs. The Ung-deficient mice do indeed have altered variable gene mutation and deficient heavy chain recombination (Rada et al., 2002) . Nilsen et al. now demonstrate that these same animals develop B-cell malignancies, indicating that if uracils are not removed, they become mutagenic. Tumors were not detected until the mice were relatively old (greater than 18 months). The fact that they were B-cell lymphomas, and not tumors of other cell types, strongly implies that Ung normally modifies DNA in the immunoglobulin loci.
Interestingly, when AID is overexpressed in transgenic mice, T-cell tumors arise, implying that aberrant AID expression initiates tumorigenesis in non-B cells (Okazaki et al., 2003) .
The mechanism of how AID deaminates cytosine to uracil is currently unraveling at a furious pace. AID prefers to deaminate cytosine on single-strand DNA rather than double-strand substrates (Bransteitter et al., 2003; Dickerson et al., 2003) . In double-strand DNA, cytosine can be deaminated when transcription occurs, suggesting that transcription opens up a small bubble which exposes the base on the nontranscribed single strand (Chaudhuri et al., 2003; Ramiro et al., 2003; Sohail et al., 2003) . The resulting uracil can be dealt with in two ways: by removing it with Ung or copying over it with a DNA polymerase. If uracil is removed, there will be a baseless site in the DNA (Figure 1a) . In B cells, lowfidelity DNA polymerases could bypass the abasic site during replication by inserting nucleotides at random on the bottom strand. Alternatively, the lesion could be repaired during base excision repair by nicking the top strand with an endonuclease. Polymerases Z (Zeng et al., 2001 ) and i (Faili et al., 2002) could then either fill in the gap with one nucleotide, or displace it and synthesize several bases. Since these polymerases are inaccurate, random mutations would be introduced at the sites of uracils. This is beneficial for antibody diversity, because mutations in variable genes can increase the affinity of the protein for antigen, and nicks in the DNA near constant genes can initiate recombination to change the molecule from IgM to IgG, IgA, or IgE.
On the other hand, if uracil is left in the DNA, as it would be in the Ung-deficient mice, it is highly mutagenic. How do uracils cause tumors? B-cell tumors have been linked to both hypermutation run amuck in bystander oncogenes, and nicking gone bad which triggers translocations of oncogenes. Concerning hypermutation, uracil is recognized as thymine by a highfidelity polymerase and pairs with adenine. Thus, a cytosine that is deaminated to uracil would become a thymine after semiconservative replication (Figure 1b) . Aberrant mutations, albeit at a lower frequency than in variable genes, have been found in regulatory and signaling genes from normal human B cells and B lymphomas. The list includes Bcl6, Iga, Igb, CD95, cmyc, Pim1, RhoH/TTF, and Pax5 (Pasqualucci et al., 2001; Gordon et al., 2003) . Thus, in Ung-deficient mice, AID may occasionally target proto-oncogenes, and the resulting uracil would produce a C : G to T : A mutation by replication past the uracil. Indeed, mutations in the genes listed above have a striking bias towards these exact substitutions (Pasqualucci et al., 2001) , suggesting that they arise by bypass of uracil.
Concerning aberrant nicking, many B-cell lymphomas have translocations of Bcl2, Bcl6, and c-myc into the immunoglobulin locus, which deregulate transcription of the genes. Some of these translocations likely happen when strand breaks are introduced into the switch regions during heavy chain class recombination. Since Ung-deficient mice have virtually no class switching, this form of strand break would be rare. However, uracil could be removed by a backup uracil DNA glycosylase, Smug1, which could initiate strand breaks. Another possibility is that during replication, DNA polymerases may actually recognize uracil in DNA as a mistake and pause before replicating the base (Figure 1b) . Recent data show that archaeal replicative polymerases do in fact stall at uracil (Greagg et al., 1999) , and this stalling may trigger repair of the lesion. If the eukaryotic polymerases d and e have a similar ability to discriminate between uracil and thymine, then the presence of uracil in the genome could theoretically lead to strand breaks.
Genetic analysis of the B-cell tumors from Ungdeficient mice will reveal if hypermutation and/or translocations are the causative event of oncogenesis. Nonetheless, it is clear that expression of AID in B cells can lead to mutations and strand breaks, whether the resulting uracil lesion is processed by Ung or not. B cells therefore walk a fine line between generating antibody diversity and tumors. 
